The EU project, Techgene, that focuses on developing next generation sequencing diagnostic tools for genetic disorders, announced that CLC bio has been selected as the software partner for this project. The goal of the Techgene project is to incorporate the novel massively parallel sequencing technology in routine diagnostic laboratories for the improved diagnosis of genetically heterogeneous diseases. To do so, the project will focus on a number of model disorders that have shown different degrees of genetic complexity. Some of these model disorders that have been selected are hemoglobinopathies, hereditary breast cancer, paraplegias, ataxias, mental retardation, and sensory disorders including blindness, deafness, and Usher syndrome. New massively parallel sequencing diagnostics will be developed for these model disorders by CLC bio. The model disorders can be considered as prototypes for a wider group of diseases. The diagnostics tools developed will be applicable to a wider range of genetic disorders.